252918 New Developments in Postpartum Hemorrhage (PPH) prevention and management: Hard to believe but true

Monday, October 31, 2011: 10:40 AM

Deborah A. Armbruster, CNM, MPH , POPPHI, PATH, Washington, WA
The field of maternal health still struggles to save the lives of women who die from PPH, but the focus has been on scaling up the tried and true evidence –based interventions.

A number of new developments in this area may change the world in which we work. Misoprostol is now on WHO's Essential Medicine List; issues of potency for oxytocin and misoprostol could have important implications for PPH prevention and women giving birth; the WHO non-inferiority trial on AMTSL vs simplified AMTSL has been completed and a number of new initiatives are starting up.

What do these developments mean for global and country programs that do the practical work of caring for mothers and newborns and saving lives?

Join us to learn about these developments that will likely initiate some significant changes in practice and programs.

Learning Areas:
Clinical medicine applied in public health
Public health or related research

Learning Objectives:
1. By the end of the session, the participants will be able to list 2 new developments in the are of PPH prevention 2. By the end of the session, the participants will identify how the new development will impact the provision of care to mothers.

Keywords: Infant Mortality, Pregnancy

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: Experience working in this field
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.